-
Signature
-
/s/ Jonathan Isler, Attorney-in-Fact
-
Stock symbol
-
BCAX
-
Transactions as of
-
Sep 17, 2024
-
Transactions value $
-
$1,260,000
-
Form type
-
4
-
Date filed
-
9/17/2024, 06:16 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
BCAX |
Common Stock |
Conversion of derivative security |
|
+863K |
|
|
863K |
Sep 17, 2024 |
Through Deerfield Partners, L.P. |
F1, F2, F3 |
transaction |
BCAX |
Common Stock |
Conversion of derivative security |
|
+863K |
|
|
863K |
Sep 17, 2024 |
Through Deerfield Private Design Fund V, L.P. |
F1, F2, F3 |
transaction |
BCAX |
Common Stock |
Purchase |
$630K |
+35K |
+4.06% |
$18.00 |
898K |
Sep 17, 2024 |
Through Deerfield Partners, L.P. |
F2, F3 |
transaction |
BCAX |
Common Stock |
Purchase |
$630K |
+35K |
+4.06% |
$18.00 |
898K |
Sep 17, 2024 |
Through Deerfield Private Design Fund V, L.P. |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
BCAX |
Series C Preferred Stock |
Conversion of derivative security |
|
-7.97M |
-100% |
|
0 |
Sep 17, 2024 |
Common Stock |
863K |
|
Through Deerfield Partners, L.P. |
F1, F2, F3 |
transaction |
BCAX |
Series C Preferred Stock |
Conversion of derivative security |
|
-7.97M |
-100% |
|
0 |
Sep 17, 2024 |
Common Stock |
863K |
|
Through Deerfield Private Design Fund V, L.P. |
F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
James E. Flynn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
Remarks:
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.